Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Australian Clinical Labs Ltd ( (AU:ACL) ) has provided an announcement.
Australian Clinical Labs announced its financial results for the half-year ended December 31, 2024, reporting a 9.46% increase in total revenue to $369.2 million. The company’s profit attributable to members surged by 136.03% to $11.7 million, reflecting strong operational performance. The interim dividend was increased to 3.50 cents per share, fully franked, indicating confidence in future growth. These results highlight ACL’s robust market positioning and its commitment to delivering value to stakeholders.
More about Australian Clinical Labs Ltd
Australian Clinical Labs (ACL) is a leading private provider of pathology services in Australia. Their NATA accredited laboratories conduct a wide range of pathology tests for clients including doctors, specialists, patients, hospitals, and corporate clients. ACL is one of the largest private hospital pathology businesses in the country, focusing on combining talented personnel, medical and scientific leadership, and innovative technologies to enhance decision-making that saves and improves patients’ lives.
YTD Price Performance: 7.56%
Average Trading Volume: 477,848
Technical Sentiment Consensus Rating: Sell
Current Market Cap: A$742.1M
Find detailed analytics on ACL stock on TipRanks’ Stock Analysis page.